Physician profile
Kevin T Foley
NPI 1861451874
$162,413,873.47
in general payments reported to CMS, 2019-2025
23 companies · $20M in 2025
The $20M reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20M · 2020: $18M · 2021: $20M · 2022: $50M · 2023: $17M · 2024: $17M · 2025: $20M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $54M · Consulting Fee: $261K · Travel and Lodging: $34K · Food and Beverage: $6,166 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $53,718,677.00 |
| Consulting Fee | $260,865.00 |
| Travel and Lodging | $34,262.31 |
| Food and Beverage | $6,165.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,695.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $92,526,690.50 | 2021-2025 | Cd Horizon Spinal System, Metrx System, Catalyft Pl Expandable Interbody System |
| Medtronic USA, INC. | $38,564,672.90 | 2019-2020 | |
| Triad Life Sciences INC. | $31,032,224.37 | 2021-2022 | |
| Digital Surgery Systems, INC. | $242,000.00 | 2025 | Aesculap |
| Alphatec Spine, INC | $27,295.02 | 2023-2025 | Other - Miscellaneous, Solus Alif, Safeop |
| Curiteva, INC. | $11,127.51 | 2021-2025 | |
| Durastat LLC | $7,033.00 | 2025 | |
| Implanet America, INC. | $722.01 | 2024-2025 | |
| Integrity Implants INC. | $467.30 | 2021-2022 | |
| Spineology INC. | $430.41 | 2023 | Optimesh Expandable Interbody Fusion System |
| Mml US, INC. | $276.78 | 2025 | Reactiv8 |
| Ecential Robotics | $234.64 | 2025 | |
| Nview Medical, INC | $181.03 | 2019-2024 | |
| Kuros Biosciences USA, INC | $154.90 | 2023 | |
| Intrinsic Therapeutics | $151.82 | 2025 | Barricaid Acd (Annular Closure Device) |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Centinel Spine, LLC | $102.76 | 2019 | |
| Viseon, INC. | $25.67 | 2024 | Maxview System - Lateral Set |
| Aesculap, INC. | $21.72 | 2020 | |
| Boston Scientific Corporation | $16.81 | 2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $15.94 | 2023 | |
| Spine Wave, INC. | $15.76 | 2020 | |
| Orthofix Medical, INC. | $12.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,271,852.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.